Latest Solid Tumor CAR-T Treatments Available in China

For over a decade, CAR-T cell therapy has been one of cancer medicine's biggest success stories - but almost entirely for blood cancers like leukaemia and lymphoma. Solid tumors, which make up the vast majority of cancer cases worldwide, remained stubbornly out of reach. That changed in 2026, when China became the first country in the world to approve a CAR-T therapy specifically for a solid tumor. If you're researching advanced cancer care options, understanding this shift - and where it's happening - matters more than ever.

A Quick Overview: What Is CAR-T Therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalised immunotherapy. Doctors draw a small sample of a patient's own T-cells (the immune system's soldiers), genetically re-engineer them in a lab to recognise a specific marker on cancer cells, multiply them into the millions, and infuse them back into the patient. Once inside the body, these "supercharged" cells hunt down and destroy tumor cells carrying that marker.

The process happens in four broad steps: T-cells are collected from the patient's blood, engineered in a lab to express the CAR receptor, expanded into the millions, and finally infused back into the patient to seek out and destroy tumor cells.

This approach revolutionised treatment for blood cancers, but solid tumors present tougher biological obstacles: they hide behind dense protective tissue, create an immune-suppressing environment around themselves, and often lack a single, uniform target marker. That is precisely why China's 2026 approval is being hailed as a milestone in global oncology.

The Breakthrough: Satri-Cel, the World's First Solid Tumor CAR-T

In June 2026, China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel), developed by Shanghai-based biotech CARsgen Therapeutics and marketed as Kaileimei. It is indicated for adults with advanced, Claudin18.2-positive, HER2-negative gastric or gastroesophageal junction cancer who have already failed at least two prior lines of treatment.

Claudin18.2 is a protein found on the surface of many gastric and pancreatic cancer cells but only in very limited amounts on healthy tissue - making it an attractive, relatively selective target for engineered T-cells.

How well does it work?

In the pivotal Phase II trial, satri-cel meaningfully outperformed standard chemotherapy across every major measure:

Outcome Measure	Satri-cel (CAR-T)	Standard Chemotherapy
Objective Response Rate (ORR)	~41%	~4%
Progression-Free Survival (PFS)	~4.7 months	~1.7 months
Median Overall Survival (OS)	9.5 months	5.5 months
Safety profile	Manageable, with monitored cytokine release syndrome	Standard chemo-related toxicities

It's important to set expectations correctly: satri-cel is not a cure, and outcomes vary by patient. But nearly doubling median survival - in patients who had already exhausted two other treatment lines - is a genuinely significant result in one of the hardest cancers to treat. Gastric cancer is among the top five deadliest cancers globally, largely because it is often diagnosed late.

Beyond Satri-Cel: What Else Is in the Pipeline?

Satri-Cel is the first approved solid-tumor CAR-T, but it isn't the only one in development. Chinese biotech and hospital-led research groups are running one of the largest solid-tumor cell therapy pipelines anywhere in the world.

Therapy / Candidate	Target	Cancer Type	Stage (2026)
Satri-cel (Kaileimei)	Claudin18.2	Gastric / GEJ adenocarcinoma	Approved (NMPA)
Satri-cel (expanded use)	Claudin18.2	Pancreatic cancer (adjuvant, post-surgery)	Phase Ib promising data
LB2102	DLL3	Small cell lung cancer, neuroendocrine carcinoma	Phase I
LCAR-C18S	Claudin18.2	Advanced solid tumors	Phase I
GPC3-targeted CAR-T	GPC3	Liver cancer (hepatocellular carcinoma)	Early phase trials
CEA-targeted CAR-T	CEA	Colorectal cancer	Early phase trials

Researchers are also exploring combination approaches - for instance, pairing CAR-T with RAS-pathway inhibitors for pancreatic cancer - to try to extend benefits further. Data presented at ESMO 2025 showed that among a small group of pancreatic cancer patients treated with satri-cel after surgery, a notably high proportion remained recurrence-free at six and nine months, suggesting the approach may eventually be used earlier in the treatment journey rather than reserved as a last resort.

Where Is This Treatment Available? Leading Cancer Centres in China

China's CAR-T ecosystem has matured rapidly, built on more than a decade of leadership in cell-therapy clinical trials - China now runs more registered CAR-T trials than any other country. Several institutions stand out as the country's most experienced Centres for cellular immunotherapy and complex oncology care:

Hospital / Cancer Centre	City	Known For
Fudan University Shanghai Cancer Centre	Shanghai	High-volume solid tumor oncology, GI cancer research
Jiahui International Cancer Centre	Shanghai	International patient access to satri-cel, bilingual care coordination
Sun Yat-sen University Cancer Centre	Guangzhou	Comprehensive cancer treatment, active CAR-T trials
Peking Union Medical College Hospital	Beijing	Academic oncology, early-phase cell therapy trials
Chinese PLA General Hospital	Beijing	Early pioneer of CAR-T clinical research in China
West China Hospital, Sichuan University	Chengdu	Large-scale oncology and hematology programs
Zhejiang Cancer Hospital	Hangzhou	Regional referral Centre for solid tumor immunotherapy

For international patients, navigating these options directly can be overwhelming - differences in language, hospital accreditation, and treatment protocols make it genuinely difficult to compare Centres from abroad. This is where MediGence helps: our team evaluates and shortlists top hospitals in China based on speciality outcomes, connects patients with the right department, and coordinates logistics such as visas, translation, and treatment planning - steps that matter as much as the science itself.

The Doctors Driving This Field

Behind every approval is a network of clinical researchers and treating oncologists. Some of the names frequently associated with China's CAR-T and gastric cancer research include:

Dr Li Zonghai - Founder and CEO of CARsgen Therapeutics, and the physician-scientist widely credited with first validating Claudin18.2 as a viable CAR-T target.
Dr Linli Xuan - Chief of Medical Oncology at Jiahui International Cancer Centre, closely involved in early clinical access to satri-cel for international patients.
Dr. Jin Li - Principal investigator on early Claudin18.2 CAR-T solid tumor trials at Shanghai East Hospital.

When researching options, patients are typically advised to look beyond a single "top doctor" label and instead evaluate a Centre's overall multidisciplinary tumor board, its CAR-T manufacturing turnaround time, and its track record managing therapy-related side effects like cytokine release syndrome - all factors that count as much as any individual surgeon or oncologist's reputation among top doctors in China oncology circles.

What Are the Risks and Limitations?

CAR-T therapy, including satri-cel, carries real risks that patients should discuss carefully with their care team:

Cytokine release syndrome (CRS): A flu-like immune reaction that can range from mild to severe, requiring close inpatient monitoring after infusion.
Neurological side effects: Less common in solid tumor CAR-T so far compared to blood cancer CAR-T, but still monitored closely.
Not a guaranteed cure: Response rates around 40% mean the majority of patients may not respond, and even responders may eventually relapse.
Eligibility is narrow: Only patients who are Claudin18.2-positive and HER2-negative, and who have already tried at least two other treatments, currently qualify.
Cost: At roughly USD 146,000 per infusion, affordability and insurance coverage remain significant barriers, especially for patients travelling internationally.

Why This Matters Globally

Gastric cancer is the fifth most common cancer worldwide, and treatment options for late-stage disease have historically been limited to chemotherapy with modest benefit. Having a genuinely new mechanism of action - one's own immune cells, re-engineered to fight the tumor - offers a fresh direction for patients who have run out of standard options.

Analysts expect the therapy to reach a few hundred patients in its first year, with the manufacturer projecting broader adoption as more hospitals gain the infrastructure to administer it. Meanwhile, U.S. and European regulators are watching closely; similar solid-tumor CAR-T candidates are in earlier trial stages elsewhere, but none has yet reached approval outside China.

References:

Fierce Pharma. "CARsgen makes history as China approves world's first CAR-T therapy for solid tumors." June 22, 2026.
Inside Precision Medicine. "Solid Tumor CAR-T Therapy Approved in China, a World First." June 2026.
Cancer Discovery, AACR. "First CAR T-Cell Therapy Approved for Solid Tumors." 2026.
Yan L, Duan B, Sun P, et al. "CAR-T cell therapy in China: innovations, challenges, and strategic pathways." Discover Oncology, 2025;16:1593.

Frequently Asked Questions

Not yet in an approved form. Several candidates are in clinical trials in the U.S. and Europe, but as of 2026, China is the only country with a formally approved solid-tumor CAR-T therapy.

Adults with advanced gastric or gastroesophageal junction cancer that is Claudin18.2-positive and HER2-negative, who have already progressed through at least two prior lines of treatment.

The most closely monitored side effect is cytokine release syndrome, an immune reaction that can cause fever and flu-like symptoms; it is generally managed in a hospital setting with supportive care.

Yes. Several Centres, including Jiahui International Cancer Centre, have established dedicated pathways for international patients, often coordinated through medical-travel platforms that assist with hospital selection, visas, and translation.

No. It significantly improves response rates and survival compared to standard chemotherapy in this trial population, but it is not described as curative, and not all patients respond.